Toframicin; The next-generation antibiotic
The next-generation aminoglycoside antibiotic
Toframicin is a semi-synthetic antibiotic which is in development for the treatment of hospital-acquired-/ventilator-associated pneumonia, bloodstream infections and neonatal sepsis.
Toframicin has ultra-broad spectrum activity, overcome drug class-related bacterial resistance, and offers an increased therapeutic window.
- Antimicrobial compounds
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
- Market entry
- Marketed product
- Joint Venture
Infectious disease area:
Multi-asset pharmaceutical companies focusing on anti-infective development.
AGILeBiotics B.V. is a pre-clinical stage biotech company focusing on the development of novel antibiotics
In addition, we are interested in developing Toframicin against MDR tuberculosis and lung infections associated with Cystic Fibrosis.